(Q42910293)

11 November 2017

Association between carbamazepine-induced cutaneous adverse drug reactions and the HLA-B*1502 allele among patients in central China (English)

1 reference

People's Republic of China

11 November 2017

0 references

author

Patrick Kwan

6

1 reference

11 November 2017

X T Wu

1

1 reference

11 November 2017

F Y Hu

2

1 reference

11 November 2017

D M An

3

1 reference

11 November 2017

B Yan

4

1 reference

11 November 2017

X Jiang

5

1 reference

11 November 2017

H Stefan

7

1 reference

11 November 2017

D Zhou

8

1 reference

11 November 2017

15 September 2010

1 reference

11 November 2017

1 reference

11 November 2017

19

1 reference

11 November 2017

405-408

1 reference

11 November 2017

3

1 reference

Risk of serious cutaneous disorders after initiation of use of phenytoin, carbamazepine, or sodium valproate: a record linkage study

11 November 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2010.08.007

Comparison and predictors of rash associated with 15 antiepileptic drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2010.08.007

Risk of Stevens-Johnson syndrome and toxic epidermal necrolysis in new users of antiepileptics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2010.08.007

HLA-B genotyping to detect carbamazepine-induced Stevens-Johnson syndrome: implications for personalizing medicine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2010.08.007

Human leukocyte antigens and drug hypersensitivity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2010.08.007

Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2010.08.007

Association between HLA-B*1502 allele and antiepileptic drug-induced cutaneous reactions in Han Chinese

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2010.08.007

Genetic basis for idiosyncratic reactions to antiepileptic drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2010.08.007

Genetic structure of the Han Chinese population revealed by genome-wide SNP variation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2010.08.007

The spectrum of Stevens-Johnson syndrome and toxic epidermal necrolysis: a clinical classification

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2010.08.007

Double-blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. UK Lamotrigine/Carbamazepine Monotherapy Trial Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2010.08.007

Medical genetics: a marker for Stevens-Johnson syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2010.08.007

Carbamazepine and phenytoin induced Stevens-Johnson syndrome is associated with HLA-B*1502 allele in Thai population.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2010.08.007

Human leukocyte antigen genotypes in carbamazepine-induced severe cutaneous adverse drug response in Japanese patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2010.08.007

HLA class I markers in Japanese patients with carbamazepine-induced cutaneous adverse reactions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2010.08.007

HLA-B locus in Caucasian patients with carbamazepine hypersensitivity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2010.08.007

A marker for Stevens-Johnson syndrome ...: ethnicity matters

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2010.08.007

Genetic predisposition of life-threatening antiepileptic-induced skin reactions.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2010.08.007

Adverse effects of antiepileptic drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2010.08.007

Safety of long-term lamotrigine in epilepsy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2010.08.007

Predictors of Lamotrigine-associated rash.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2010.08.007

Lamotrigine-associated rash: risk/benefit considerations in adults and children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2010.08.007

Rash from antiepileptic drugs: influence by gender, age, and learning disability

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2010.08.007

10.1016/J.YEBEH.2010.08.007

7 January 2021

Identifiers

DOI

1 reference

11 November 2017

1 reference